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Cytokines are intercellular mediators involved in viral control and liver damage being induced by infection with hepatitis C
virus (HCV). The complex cytokine network operating during initial infection allows a coordinated, effective development of
both innate and adaptive immune responses. However, HCV interferes with cytokines at various levels and escapes immune
response by inducing a T-helper (Th)2/T cytotoxic 2 cytokine profile. Inability to control infection leads to the recruitment of
inflammatory infiltrates into the liver parenchyma by interferon (IFN)-gamma-inducible CXC chemokine ligand (CXCL)-9, -10,
and -11 chemokines, which results in sustained liver damage and eventually in liver cirrhosis. The most important systemic HCV-
related extrahepatic diseases—mixed cryoglobulinemia, lymphoproliferative disorders, thyroid autoimmune disorders, and type
2 diabetes—are associated with a complex dysregulation of the cytokine/chemokine network, involving proinflammatory and
Th1 chemokines. The therapeutical administration of cytokines such as IFN-alpha may result in viral clearance during persistent
infection and reverts this process.
1. Introduction
Cytokines are small soluble proteins secreted by immune sys-
tem cells and other cells and are part of an intercellular com-
munication system responsible for immune response [1].
These proteins play their role by binding specific cell recep-
tors that either induce or inhibit cytokine-regulated genes.
During viral infection, various cytokines play a role both in
viral clearance and tissue damage [1].
2. Cytokines
Over 100 different cytokines have been reported, which are
classified according to their primary role. In relation to their
functions, cytokines can be classified in subgroups: (a) pro-
inflammatory cytokines (interleukin (IL)-1, IL-6, tumor ne-
crosis factor (TNF)-alpha); (b) T-helper (Th)1 cytokines,
which are produced by Th1-activated lymphocytes (inter-
feron (IFN)-gamma, IL-12, IL-18); (c) Th2-type cytokine
which plays a role in the inhibition of cytokines derived from
Th1 cell which turns out to downregulate the function of Th1
immune responses, inhibiting antigen-presenting capacity of
macrophage and promoting B-cell proliferation and there-
fore antibody production (IL-10, IL-4, IL-5, IL-13); (d) Th17
cytokines which are important for the differentiation of Th17
lymphocytes. IL-23, together with IL-6 and transforming
growth factor (TGF)-beta, leads to the differentiation of Th0
to Th17 cells which carry out the function of secreting IL-
17A, IL-17F, TNF-alpha, and IL-1 thus leading to proinflam-
matory reaction [1].
3. Chemokines
Chemokines are a large multifunctional family of cytokines
(chemotactic cytokines) that induce the migration of cells
to sites of infection or injury. Functionally chemokines fall
into two main categories: homeostatic or proinflammatory.
Homeostatic chemokines are produced constitutively; these
are generally involved in lymphocyte trafficking, immune
surveillance, and localization of lymphocytes with antigen
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in the lymphatic system [2]. Other chemokines are only
produced by cells during infection or following a proinflam-
matory stimulus and prompt the migration of leukocytes to
an injured or infected site. Such inflammatory chemokines
can also activate cells to raise an immune response.
Chemokines are structurally related, because most of
them contain four invariant cysteine residues. Depending on
the arrangement of the first two of these cysteines, chemok-
ines are divided into four subfamilies: CXC (alpha), CC
(beta), C (gamma), and CX3C (delta) [3]. Chemokines are
produced as propeptides and are cleaved during secretion to
produce an active mature protein [4] that functions by acti-
vating G-protein-coupled receptors. The receptors for these
chemokines have been termed accordingly as CXCR, CCR,
CR, and CX3CR [5].
4. Hepatitis C Virus (HCV) and
Immune Response
HCV is a hepatotropic, noncytopathic virus of the family
Flaviviridae, which induces both acute and chronic necro-
inflammatory liver disease [6, 7]. HCV escapes immune con-
trol in 60–85% of cases. When infecting the liver parenchy-
ma, HCV continuously releases viral particles into the blood
stream. The first line of defense that HCV will encounter
includes natural killer (NK) cells and natural killer T (NKT)
cells [8]. These cells are activated by type 1 IFN (alpha and
beta) released by infected liver cells. NK and NKT cells
constitute a relevant source of IFN-gamma and TNF-alpha
[9]. These cytokines inhibit viral replication without de-
stroying liver cells. NK cells are activated by IL-12 released
from dendritic cells (DCs) and thus become empowered to
eliminate infected cells [10]. NK cells may also induce partial
or total DCs maturation [11].
DCs can process viral antigens and present them to spe-
cific immune system cells via class I and class II major histo-
compatibility complex (MHC) molecules. DCs capture viral
particles through Toll-like receptors (TLRs). Upon activa-
tion, DCs secrete several types of cytokines (IL-12, TNF-
alpha, IFN-alpha, IL-10) that will regulate and polarize the
response of adjacent cells [12]. Mature DCs leave the liver
after viral epitope collection and head for lymph nodes,
where they will activate T cells in the specific immune system
[13].
Cytokines released in the liver parenchyma induce che-
mokine release by liver cells, including IFN-gamma-induci-
ble protein (IP-10/CXCL10), IFN-gamma-induced monoki-
ne (MIG/CXCL9), IFN-inducible T-cell alpha chemoattrac-
tant (I-TAC/CXCL11), macrophage inflammatory protein
(MIP)-1alpha (MIP/CCL3), andMIP-1beta/CCL4, which re-
cruit [14] specific cells capable of infection control.
Mature DCs and immature T cells, both of which express
chemokine receptor CCR7, are recruited towards lymph
nodes by secondary lymphoid-tissue cytokine (SLC/CCL21)
[13]. In the lymph node, T cells expressing T-cell receptors
(TCRs) appropriate for the recognition of epitopes presented
by DCs in their MHC molecules are activated. The inter-
action between the TCR and MHC-viral epitope complex
results in specific T-cell activation. Certain specific CD8
T cells, cytotoxic T lymphocytes (CTLs), become cytolytic,
secrete type 1 cytokines, and travel to the infected liver [15–
17]. Specific CD4+ T cells will regulate the adaptive response
by secreting Th1 cytokines (IL-2, IFN-gamma, TNF-alpha)
to facilitate a cell-mediated immune response and Th2 cytok-
ines (IL-4, IL-10, IL-13) to regulate the humoral immunity
[18]. It is widely accepted that adaptive immune response
plays a key role in the control of HCV infection.
5. Cytokines and HCV Chronic Infection
HCV manages to escape immune response. To this end they
interfere with various immune mechanisms including cytok-
ine activity modulation.
5.1. Innate Immunity. A primary cell defense mechanism
during initial infection is the synthesis of antiviral type 1
IFN-alpha/beta [19]. On binding its receptor, IFN-alpha/
beta activates a number of intracellular mechanisms that can
prevent viral replication and spread to other liver cells. HCV
is a good inducer of IFN-alpha/beta expression [20]. Howev-
er, HCV seems to be, at least in part, unresponsive to IFN-
alpha/beta effects and may effectively replicate in the liver
despite such gene induction. HCV can block type 1 IFN in-
duction; this possibly results from the fact that nonstructural
proteins (NS 3 and NS5A), and structural protein E2 may
both potentially block the expression and transcription of
IFN-alpha/beta-induced genes. HCV NS5A protein induces
IL-8 expression, which is associated with IFN-alpha inhibi-
tion [21].
The outcome of a viral infection depends on the interplay
between the host capacity to trigger potent antiviral respons-
es and viral mechanisms that counteract them. Although
Toll-like receptor (TLR)-3, which recognizes virally derived
double-stranded (ds) RNA, transmits downstream antiviral
signaling through the TIR adaptor Trif (TICAM-1), viral
RNA-sensing RIG-like helicases (RLHs) use the mitochon-
drial-bound CARD protein Cardif (IPS-1/MAVS/ISA). The
importance of these two antiviral signaling pathways is re-
flected by the fact that both adaptors are inhibited through
specific cleavage triggered by the HCV serine protease NS3-
4A [22, 23].
NK cells and NKT cells exert their antiviral action
through direct, non-MHC-restricted cytotoxic mechanisms
and IFN-gamma production [24]. In addition, they allow
maturation for DCs favoring the development of Th1/Tcy-
totoxic (Tc)1 responses [10]. However, they do not seem to
play a significant role in acuteHCV infection [25]. It has been
suggested that HCV can block NK cells and NKT cells func-
tions thus preventing antiviral cytokines such as IFN-gamma
from being produced, via an interaction between HCV E2
protein and NK-cell CD81 molecule [26].
During chronic infection with HCV, a decrease in IFN-
alpha production by plasmacytoid DCs has been reported
[27], such as a decrease in IL-12 production by myeloid DCs
[28]. In fact, HCV structural proteins can interact with TLR-
2 in monocytes and induce IL-10 production, which inhibits
IL-12 and IFN-alpha production in DCs [29]. However,
other studies reported an increased IFN-alpha production,
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especially in patients who fail to respond to exogenous IFN-
alpha, in whom IFN-stimulated genes (ISGs) are highly acti-
vated [30].
It has been also suggested that DCs cytokine profile
cannot polarize T-cell responses towards a Th1/Tc1 response
[31] and contributes to inadequate NK cells and NKT cells
activation. However, other studies have shown that a pro-
gressive liver injury in chronic hepatitis C infection correlates
with increased intrahepatic expression of Th1-associated cy-
tokines [32, 33].
5.2. Adaptive Response. HCV CD4+-T cells play a key role
in adaptive response in that they provide help in activating
cytotoxic and humoral responses. They can secrete Th1-
cytokines including IFN-gamma, which favors neutrophil
and macrophage recruitment and leads to inflammatory re-
sponse. They also may release Th2 cytokines such as IL-4
and IL-10, which limit Th1 cytokine-mediated response and
favor the development of humoral response [34]. A multis-
pecific, strong, sustained, CD4+-T-cell-specific Th1 response
may be seen in infections with HCV infection evolving to
resolution [35]. However, when infection becomes chronic,
a weak CD4-T-specific response with few specificities and
scarce type 1 cytokine production is observed [36].
CD8+ CTLs can clear viruses using apoptosis-related cy-
tolytic mechanisms and mechanisms mediated by type 1 cy-
tokines (IFN-gamma, TNF-alpha). In chronic infection with
hepatitis B virus or HCV, specific CTLs are few and engage
few specific targets; they also display anergic characteristics
with reduced type 1 cytokine secretion [37]. Another poten-
tial mechanism of blocked type 1 cytokine production results
from regulatory T-cell activity. These cells can release IL-10
and TGF-beta and inhibit proliferation and cytokine synthe-
sis in T cells, either directly or through other cytokines, in
hepatitis C [38].
Cytokines produced by T cells play a role in the regulation
of humoral responses; nevertheless, these responses cannot
control chronic viral hepatitis, even though they play a role
in the pathogenesis of extrahepatic manifestations [18].
6. Cytokines and Liver Damage
When specific immune response fails to control viral rep-
lication, the infected liver cells secrete IFN-gamma-in-
duced chemokines such as CXC chemokine ligand CXCL9,
CXCL10, and CXCL11, which result in the migration of
nonspecific mononuclear cells into the liver [39], which are
unable to control infection but result in sustained liver dam-
age [40]. Inhibition of these chemokines limits nonspecific
cell migration and hence reduces the inflammation [41].
The recruitment of persistent mononuclear infiltrates leads
to the development of chronic inflammation, which results
in sustained liver damage. Finally, chronic inflammation in-
duces regenerating mechanisms in the liver parenchyma.
Several factors influence this process, including cytokines
such as IL-6, TNF-alpha, TGF-beta, hepatocyte growth fac-
tor, and epidermal growth factor. These and other factors
activate transcription factors such as nuclear factor-κB, signal
transducer, and activator of transcription 3 which initiate the
gene expression cascade leading to hepatocyte proliferation
[42].
Persistent inflammation also activates hepatic stellate
cells, myofibroblasts, and fibroblasts, which favors the devel-
opment of liver fibrosis. The activation of these cells is regu-
lated by pro-inflammatory cytokines such as TGF-beta, IL-
6, TNF-alpha, CCL21, and platelet-derived growth factor,
among other stimuli [43].
7. HCV-Related Extrahepatic
Diseases (HCV-EHDs)
HCV is known to be responsible for both hepatic and HCV-
EHDs. The most important systemic HCV-EHDs are HCV-
relatedmixed cryoglobulinemia (MC) (MC+HCV) and lym-
phoproliferative disorders, while the most frequent and clin-
ically important endocrine HCV-EHDs are autoimmune
thyroid disorders (AITDs).
8. Cytokines, Cryoglobulinemia, and
Lymphoproliferation
MC is a distinct syndrome clinically characterized by pur-
pura, weakness, arthralgia, and involvement of one or more
organ systems, including membranoproliferative glomeru-
lonephritis, peripheral neuropathy, skin ulcers, liver damage,
and diffuse vasculitis. Cryoprecipitable immunocomplexes,
namelymixed (IgG-IgM) cryoglobulins, are the serological
hallmark of the disease: IgG is the autoantigen and IgM,
with rheumatoid factor (RF) activity, the autoantibody. MC
is classified in type 2 and type 3 according to the presence of
polyclonal or oligo-monoclonal IgMs. Because expansion of
RF-producing B cells is the underlying disorder of MC, this
condition is considered a “benign” B-cell lymphoprolifera-
tive disease [44, 45].
The mechanism(s) responsible for the lymphoprolifera-
tion surroundingMC remain unknown. Due to geographical
heterogeneity in prevalence of MC+HCV, it is conceivable
that unknown genetic and/or environmental factors may
influence the development of this syndrome [46]. Several
data are consistent with the possibility that chronic stimula-
tion of B cells by viral epitopes could play an important role
[47–49].
A wide body of evidence, in addition, strongly suggests
that a key factor in the pathogenesis of MC+HCV is repre-
sented by the inhibition of the apoptosis of B cells, leading
to their progressive accumulation. First, this is suggested
by the histopathological characteristics of liver and/or bone
marrow lymphocyte infiltrates in MC patients [50], as well
as by the high prevalence of bcl-2 rearrangement (t(14;
18) translocation) in patients with MC, with regression of
translocated B-cell clones after successful antiviral therapy
[45, 51, 52].
Furthermore, B-lymphocyte stimulator (BLyS) serum
levels are significantly correlated with B-cell proliferation
during chronic HCV infection. These results strongly suggest
a role for BLyS in the induction and expression of HCV- B-
cell proliferation [53–55]. Chemokine CXCL13, also known
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as BCA-1 (B cell-attracting chemokine-1) or BLC (B-lym-
phocyte chemoattractant), is a major regulator of B-cell
trafficking. HCV infection may be associated with B-cell
dysfunction and lymphoproliferative disorders, including
MC+HCV. The results by Sansonno et al. [56] indicate that
upregulation of CXCL13 gene expression is a distinctive
feature of HCV-infected patients. Higher levels of this che-
mokine in the liver as well as in the skin of patients with
active MC+HCV vasculitis suggest a possible interrelation
between these biologic compartments.
Recently, Saadoun et al. [57] studied the local immune
response in the liver, which is considered the principal site
for immune reactions involved in MC pathogenesis. In that
study, the cytokine profile of liver-infiltrating T lymphocytes
from MC+HCV patients and without MC (of type 2) were
compared. They showed that, although no differences were
found in the proportion of CD4+, CD8+ liver T cells, the
ability of freshly isolated liver T cells to produce type 1 cy-
tokines in response to stimulation with phorbol myristate
acetate and ionomycin for 6 hours was significantly higher in
MC+HCV patients than in HCV-infected controls without
MC, whereas production of type 2 cytokines by these cells
was similar (IL-4) or reduced (IL-10).
This agrees with previous data obtained in peripheral
blood mononuclear cells [58], ruling out the possibility of
a discrepancy between the response of peripheral and liver
T cells. Interestingly, in both studies by Saadoun et al. and
Loffreda et al. [57, 58], a reduced expression of IL-10 (a
strong inhibitor of IFN-gamma production) is demonstrated
regardless of the different sources. These observations sug-
gest that the evolution of HCV infection toward MC is char-
acterized by a strong Th1 response.
Several studies have shown an increased expression of
IFN-gamma [59] and IFN-gamma-inducible chemokines
[60], in particular CXCL10, in hepatocytes and in lympho-
cytes of HCV-infected patients [61, 62], directly related with
the degree of inflammation and with an increase of circulat-
ing levels of IFN-gamma and CXCL10 [14, 63–66].
Furthermore, it has been shown that NS5A and core
proteins, alone or by the synergistic effect of cytokines, such
as IFN-gamma and TNF-alpha, are capable of upregulating
CXCL10 and CXCL9 gene expression and secretion in cul-
tured human hepatocyte-derived cells [67], suggesting that
CXCL10 produced by HCV-infected hepatocytes could play
a key role regulating T-cell trafficking into a Th1-type inflam-
matory site as the liver tissue during chronic HCV infection,
by recruiting Th1 lymphocytes that secrete IFN-gamma and
TNF-alpha, which induce CXCL10 secretion by hepatocytes,
thus perpetuating the immune cascade [68].
Furthermore, we have recently shown that circulating
CXCL10, CXCL11, IFN-gamma-inducible (Th1) chemoki-
nes are higher in patients with MC+HCV than in chronic
hepatitis C (CHC) patients. Moreover, our studies demon-
strate markedly high serum levels of CXCL10 and CXCL11
in patients with MC+HCV compared to healthy controls
in particular in the presence of active vasculitis. A strong
relationship between circulating IFN-gamma and CXCL11
was shown, strongly supporting the role of a Th1 immune
response in the pathogenesis of MC+HCV patients [69–74].
For comparison the prototype Th2 chemokine (C-C
motif) ligand 2 (CCL2) was not significantly different in
patients with MC+HCV and active vasculitis than in MC
patients, and it suggests that the Th1 CXCL10 chemokine is
specifically involved in the appearance of vasculitis in these
patients [74].
The pro-inflammatory cytokines IL-1beta, IL-6, and
TNF-alpha have also been evaluated in MC+HCV patients.
In fact, MC+HCV patients show significantly higher mean
IL-1beta, IL-6, and TNF-alpha levels than the controls or the
HCV patients. If the importance of IL-1beta and IL-6 in the
pathogenesis of MC is confirmed, these results will open the
way for the evaluation of new therapies for MC [75].
On the whole the above-mentioned data underline the
importance of the activation of the Th1 immunity in the
immunopathogenesis of MC+HCV, but suggest a complex
dysfunction of the cytokine/chemokine network in these pa-
tients, involving also pro-inflammatory cytokines.
9. Cytokines and AITDs Associated with
HCV and MC
The pattern of thyroid disorders observed in HCV infection
is characterized by the presence of increased circulating levels
of antithyroid peroxidase antibody (AbTPO) and increased
risk of hypothyroidism in AbTPO positive subjects [76–80].
This pattern is similar to that observed in IFN-alpha-
treated patients, too [81].
Differences in geographical distribution [82], genetic
variability in the populations studied [83], and environmen-
tal cofactors, such as iodine intake or other infectious agents
[84, 85], could play an important role in the development of
AITD.
Recently it has been shown that high levels of CXCL10
are present in patients with autoimmune thyroiditis (AT),
in particular in the presence of hypothyroidism [68], and
an involvement of Th1 immune response in the induction
of AT [86], Graves’ disease, and Graves’ ophthalmopathy
[87] has been shown. Furthermore, the presence of HCV in
the thyroid of chronically infected patients has been recently
demonstrated [88, 89]; however, other studies are needed to
furtherly confirm this point.
On the above-mentioned bases, it has been speculated
that HCV thyroid infection may act by upregulating CXCL10
gene expression and secretion in thyrocytes (as previously
shown in human hepatocytes [67]) recruiting Th1 lympho-
cytes that secrete IFN-gamma and TNF-alpha, which induce
CXCL10 secretion by thyrocytes, thus perpetuating the im-
mune cascade, that may lead to the appearance of AITDs in
genetically predisposed subjects.
This hypothesis has been recently confirmed by two stud-
ies that demonstrated high serum levels of CXCL10 in
MC+HCV patients and showed that CXCL10 is significantly
higher in the presence of AT compared toMC+HCV patients
without thyroiditis [90, 91]. For comparison the prototype
Th2 chemokine CCL2 was not significantly different in
patients with MC+HCV in the presence of AT than in
MC+HCV patients, and it suggests that the Th1 CXCL10
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chemokine is specifically involved in the appearance of AT
in these patients [91].
Among the pro-inflammatory cytokines, IL-1beta and
TNF-alpha were not associated with the presence of AT in
MC+HCVpatients, while IL-6 wasmodestly but significantly
increased in patients with AT [71, 92].
On the whole the above-mentioned data underline the
importance of the activation of the Th1 immunity in the
immunopathogenesis of AT in patients with MC+HCV.
10. Cytokines and Type 2 Diabetes Mellitus
(T2DM) Associated with HCV and MC
Several clinical epidemiological studies since 1994 have re-
ported that HCV infection is linked to diabetes [93]. The as-
sociation betweenHCV infection, in patients without cirrho-
sis (a well-known risk factor for T2DM), and T2DMhas been
first studied in two of our studies, in patients with chronic
HCV infection (HCV+) associated with MC (MC+HCV)
[94] and in patients with HCV-related chronic liver disease
[95].
There is one population study (National Health and Nu-
trition Examination Survey-NHANES III 1988–1994) that
showed an adjusted odds ratio of 3.8 for T2DM for those who
were aged >40 years and HCV+ [96] and increased incidence
of T2DM [97].
There have been a few reports, too, that IFN treatment
of HCV infection improves glucose tolerance [94, 98] when
HCV infection is eradicated; however, another study did not
confirm these results [99].
Altogether the above-mentioned data indicate that HCV
chronic infection is a risk factor for developing T2DM.
10.1. Mechanism
10.1.1. Insulin Resistance and Steatosis. It is speculated that
insulin resistance (as a consequence of hepatic steatosis (i.e.,
present in about 50% of the subjects with HCV infection)
[93] and/or elevated expression of TNF-alpha (strongly cor-
related with the degree of liver diseases and the level of insu-
lin resistance) [89]) may lead to the development of T2DM
[93].
10.1.2. Direct Islet Cell Destruction by HCV. Masini et al.
[100] recently demonstrated a direct cytopathic effect of
HCV at the islet cell level.
10.1.3. Possible Autoimmune Induction. The type of diabetes
manifested by patients with HCV chronic infection is not the
classical T2DM. The labelling of HCV+ patients as T2DM
is purely conventional and possibly inaccurate: the lines
separating type 1 diabetes from latent autoimmune diabetes
in adults (LADA) and from T2DM are fading away as new
pathogenetic information is obtained [101].
Three studies have previously reported [94, 95, 102] that
HCV+ patients T2DM were leaner than T2DM controls and
showed significantly lower LDL-cholesterol and systolic and
diastolic blood pressure. Furthermore, MC-HCV+ patients
with T2DM had non-organ-specific autoantibodies more
frequently (34% versus 18%) than nondiabetic MC-HCV+
patients [94].
An immune-mediated mechanism for MC-HCV+ asso-
ciated diabetes has been postulated [94], and a similar path-
ogenesis might be involved in the diabetes of HCV+ patients.
This hypothesis is strengthened by the finding that autoim-
mune phenomena in T2DM patients are more common
than previously thought [103]. Since the prevalence of classic
beta-cell autoimmune markers in HCV+ patients has not
been found to be increased [89], other immune phenomena
might be involved [104].
On the above-mentioned bases, it could be interesting
to speculate that HCV infection of beta cells [100] may
act by upregulating CXCL10 gene expression and secretion
(as previously shown in human hepatocytes) recruiting Th1
lymphocytes that secrete IFN-gamma and TNF-alpha, which
induce CXCL10 secretion by beta cells, thus perpetuating the
immune cascade that may lead to the appearance of beta cells
dysfunction in genetically predisposed subjects.
This hypothesis has recently been confirmed by a study
that demonstrates higher serum levels of CXCL10 in HCV+
patients with T2DM with respect to those without [64, 105].
11. Therapeutic Role of Cytokines in
Chronic Viral Hepatitis
IFN-alpha is the only cytokine currently used in the treat-
ment of chronic viral hepatitis. In CHC, pegylated IFN-alpha
combined with ribavirin leads to sustained viral clearance in
50% of patients [106]. The most important effect of IFN-
alpha is directly antiviral; however, it has also immunomodu-
lating actions that favor Th1/Tc1 response restoration [107–
109]. On the other hand, ribavirin, a wide-spectrum antivi-
ral agent used in combination therapy for hepatitis C, has
immunomodulating effects that induce type 1 cytokine pro-
duction [110]. Sustained viral load reduction with antiviral
agents has also been seen to facilitate specific T response re-
covery with type 1 cytokine production in hepatitis C [111].
An exogenous administration of Th1-inducing cytokines
such as IL-12 [112] or anti-inflammatory cytokines such as
IL-10 has also been attempted to reduce intrahepatic inflam-
mation severity [113]. However, such therapies remain ex-
perimental, and their effectiveness is unclear.
From a theoretical standpoint Tc1-associated chemokine
receptors may represent an interesting therapeutic target in
the development of drugs for patients with chronic hepatitis
unresponsive to antiviral agents, their aim being a reduction
of liver inflammation and progression to fibrosis by blocking
inflammatory cell migration into the liver [39, 41].
Treatment-induced and spontaneous clearance of HCV
infection are affected by various host factors. Polymorphisms
in the region of the gene IL-28B are associated with HCV
clearance, implicating the gene product, IFN-lambda3, in
the immune response to HCV. Although it is not clear how
the IL-28B haplotype affects HCV clearance, IFN-lambda3
upregulates IFN-stimulated genes, similar to IFN-alpha and
-beta, but via a different receptor. There is also evidence that
IFN-lambda3 affects the adaptive immune response.
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It is known that IL-28B may establish a robust T-
cell adaptive immune response [114, 115]. This effect may
explain the relationship between single-nucleotide polymor-
phism (SNPs) near IL-28B, adaptive response, and viral
clearance [116].
The IL-28B genotype can be considered, along with
other factors, in predicting patient responses to therapy with
pegylated IFN-alpha and ribavirin [117, 118].
Clinical studies assessing safety and efficacy in the treat-
ment of HCV with exogenous IFN-lambda3 are currently
underway. Early results suggest that IFN-lambda3 treatment
inhibits HCV replication and is associated with a limited
side effect profile. However, hepatotoxicity in both healthy
volunteers and HCV-infected patients has been described
[119].
12. Conclusion
Cytokines are intercellular mediators involved in viral con-
trol and liver damage as induced by infection with HCV. The
complex cytokine network operating during initial infection
allows a coordinated, effective development of both innate
and adaptive immune responses. However, HCV interferes
with cytokines at various levels and escape immune response
by inducing a Th2/Tc2 cytokine profile. Inability to control
infection leads to the recruitment of inflammatory infiltrates
into the liver parenchyma by IFN-gamma-inducible CXCL9,
-10 and -11 chemokines, which results in sustained liver
damage and eventually in liver cirrhosis; however, fibrogen-
esis may also follow distinct paths. The most important sys-
temic HCV-EHDs—MC, lymphoproliferative disorders, and
AITDs—are associated with a complex dysregulation of the
cytokine/chemokine network, involving pro-inflammatory
and Th1 chemokines. The therapeutical administration of
cytokines such as IFN-alpha may result in viral clearance
during persistent infection and reverts this process.
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